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Abstract
Objective—To evaluate whether changes
in concentrations of circulating adhesion
molecules are related to disease activity in
patients with giant cell arteritis (GCA).
Methods—A sandwich ELISA was used to
measure soluble intercellular adhesion
molecule-1 (sICAM-1), sICAM-3, vascular
cell adhesion molecule-1 (sVCAM-1),
E-selectin (sE-selectin), and L-selectin
(sL-selectin) in serum and plasma samples
from patients with GCA. A cross sectional
study was performed on 64 GCA patients
at diVerent activity stages and on 35 age
and sex matched healthy donors. Thirteen
of these patients were evaluated at the time
of diagnosis and serially during follow up.
Results—At the time of diagnosis,
sICAM-1 concentrations were significantly
higher in active GCA patients than in con-
trols (mean (SD) 360.55 (129.78) ng/ml ver-
sus 243.25 (47.43) ng/ml, p<0.001). In
contrast, sICAM-3, sVCAM-1, sE-selectin,
and sL-selectin values did not diVer from
those obtained in normal donors. With
corticosteroid administration, a decrease
in sICAM-1 concentrations was observed,
reaching normal values when clinical re-
mission was achieved (263.18 (92.7) ng/ml
globally, 293.59 (108.39) ng/ml in the group
of patients in recent remission, and 236.83
(70.02) ng/ml in those in long term remis-
sion). In the 13 patients followed up
longitudinally, sICAM-1 values also nor-
malised with clinical remission (225.87
(64.25) ng/ml in patients in recent remis-
sion, and 256.29 (75.15) ng/ml in those in
long term remission).
Conclusions—Circulating sICAM-1 con-
centrations clearly correlate with clini-
cally apparent disease activity in GCA
patients. DiVerences with results previ-
ously found in patients with other vascu-
litides may indicate that diVerent
pathogenic mechanisms contribute to
vascular inflammation in diVerent dis-
orders.
(Ann Rheum Dis 1999;58:189–192)
Giant cell (temporal) arteritis (GCA) is a large
vessel vasculitis that aVects mostly elderly peo-
ple. Histologically, it is characterised by a lym-
phocyte and macrophage infiltration of large
and medium sized vessels that frequently
exhibits a granulomatous pattern with giant
cell formation. There is no specific treatment
for this disease, although GCA patients present
a favourable clinical and biological response to
corticosteroids. However, relapses are not
infrequent when corticosteroids are tapered or
discontinued, and accurate parameters dis-
criminating persistent subclinical inflamma-
tory activity from true remission have not been
identified.1
Important contributions have currently im-
proved our understanding of the immuno-
pathogenic mechanisms involved in the devel-
opment of GCA lesions. T lymphocytes
infiltrating the temporal arteries seem to be
activated by specific recognition of a putative
antigen residing in the arterial wall and, subse-
quently, activate macrophages, which undergo
a functional diVerentiation and contribute to
vessel inflammation and damage through vari-
ous pathways (see reviews by Cid et al1 and
Weyand and Goronzy2).
Independently of the primary immuno-
pathogenic mechanisms, the development of
inflammatory infiltrates requires dynamic in-
teractions between leucocyte surface adhesion
receptors and their ligands on the endothelial
cell surface (reviewed by Springer3). Circulat-
ing forms of these adhesion molecules have
been detected in human serum and plasma and
increased concentrations have been detected in
disorders where leucocyte/endothelial cell in-
teractions play a significant part, namely infec-
tions, neoplasms, and chronic inflammatory
diseases.4 The role that circulating adhesion
molecules play in vivo is not well known. It has
been suggested that increased circulating
concentrations of soluble adhesion molecules
may reflect endothelial or leucocyte activation,
or both.5
In this study, we measured circulating
concentrations of soluble ICAM-1, ICAM-3,
VCAM-1, E-selectin, and L-selectin in a large
and homogeneous series of patients with
biopsy verified GCA to define the pattern of
circulating adhesion molecules in GCA pa-
tients and to evaluate whether changes in solu-
ble adhesion molecule concentrations are
related to disease activity.
Methods
PATIENTS
The study group consisted of 64 biopsy verified
GCA patients (18 men and 46 women) aged 74
years (range 57–88).
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A cross sectional study was performed, and
patients were classified according to their
disease activity. GCA was considered active
when patients were clinically symptomatic and
evaluated before starting treatment (pred-
nisone 1 mg/kg/day). Patients were considered
to be in remission when they fulfilled all the
following conditions: (a) none of the GCA
related signs or symptoms present at the time
of diagnosis was present anymore, (b) there
were no new signs or symptoms attributable to
GCA, and (c) erythrocyte sedimentation rate
(ESR) was within the normal range. Among
them, we considered separately patients treated
for one month to two years in whom remission
was mantained with corticosteroid treatment
(recent remission), and patients who, having
been treated for at least two years, no longer
were receiving corticosteroids (long term
remission).
Data concerning clinical manifestations at
diagnosis were obtained prospectively in pa-
tients with active disease and in those in recent
remission. In patients in long term remission,
clinical manifestations at presentation were
obtained from their records. Disease activity
was evaluated prospectively in all patients.
Clinical features recorded were age, sex, dura-
tion of symptoms before biopsy, and the
presence or absence of the following: polymyal-
gia rheumatica, cranial symptoms (headache,
scalp tenderness, jaw claudication), ischaemic
symptoms (amaurosis, diplopia, cerebrovascu-
lar accident), and systemic inflammatory re-
sponse (fever, weight loss, ESR > 85 mm 1st h,
haemoglobin < 110 g/l).
The control group included 35 healthy blood
donnors (10 men, 25 women) aged 73 years
(range 60–88).
For the cross sectional study, 73 determina-
tions (49 serum samples, 24 plasma samples)
were made: 45 in active GCA patients, and 28
in patients in remission (13 in recent remission
and 15 in long term remission).
A longitudinal substudy was done with 13
active patients who underwent serial determi-
nations at diagnosis (with no treatment), when
in complete remission one month to two years
after starting corticosteroid treatment (recent
remission), and when in long term remission,
no longer receiving treatment. None of these
patients experienced significant relapses during
their follow up. For that reason, months/years
after the start of treatment were considered
equivalent to months/years in clinical remis-
sion.
SOLUBLE ADHESION MOLECULE DETECTION
All samples were analysed for sICAM-1,
sICAM-3, sVCAM-1, sE-selectin, and sL-
selectin values by sandwich ELISA according
to the instructions of the manufacturer. We
used commercially available kits from British
Biotechnology Products, Abingdon, UK, for
sICAM-1, sVCAM-1, and sE-selectin (BBE
1B, BBE 2B, and BBE 3B respectively), and
kits from Bender Medsystems, Vienna, Austria,
for sICAM-3 and sL-selectin (BMS 218 and
BMS 206 respectively).
STATISTICAL ANALYSIS
Data are presented as means (SD). For the
cross sectional study, a Kruskal-Wallis H test
was used, correcting p values for multiple com-
parisons. For the longitudinal study, a Wilcox-
on’s rank sum test was used, also correcting p
values for multiple comparisons. The Mann-
Whitney U test was used for comparisons
between two groups. Pearson’s correlation
coeYcient was used to correlate continuous
variables. p Values (two tailed) less than 0.05
were considered significant.
Results
No diVerences were found between serum and
plasma concentrations of sICAM-1, sICAM-3,
sVCAM-1 nor sL-selectin (p = 0.42, 0.86,
0.17, and 0.35 respectively). Plasma sE-
selectin concentrations were significantly lower
than serum concentrations (p < 0.01). There-
fore, for sE-selectin, only serum samples were
considered.
Soluble ICAM-1 concentrations in active
patients (360.55 (129.78) ng/ml) were in-
creased compared with controls (243.25
(47.43) ng/ml) (p < 0.001 ). Soluble ICAM-1
concentrations were higher in active patients
than in patients in clinical remission, both
when these were considered globally (263.18
(92.7) ng/ml, p < 0.01), and when only patients
in long term remission were considered
(236.83 (70.02) ng/ml, p < 0.01). Circulating
sICAM-1 values in patients in clinical remis-
sion did not diVer from normal donors. No
significant diVerences were observed, either,
between patients in recent remission (293.59
(108.385) ng/ml) compared with those in long
term remission (table 1).
No statistical diVerences were found in
sICAM-3, sVCAM-1, sE-selectin, and sL-
selectin values between active patients and
controls, nor between active patients and
patients in remission (table 1).
Table 1 Concentrations of the adhesion molecules studied in the cross sectional study (ng/ml)*
Adhesion
molecule Active patients (n=45)
Patients in remission
Controls (n=35)
Recent remission
(n=13)
Long term remission
(n=15) Total (n=28)
sICAM-1 360.55 (129.78)†‡ 293.59 (108.385) 236.83 (70.02) 263.18 (92.71) 243.25 (47.43)
sICAM-3 38.4 (20.6) 44.64 (23) 43.71 (20.829) 44.14 (21.46) 35.26 (24.674)
sVCAM-1 705.21 (278.84) 817.76 (508.69) 622.34 (353.1) 713.07 (435.32) 661.19 (254.64)
sE-selectin 44.46 (28.6) 50.36 (33) 39.84 (26.02) 43 (27.82) 38.33 (31.12)
sL-selectin 540.13 (321.07) 627.03 (407.68) 652.63 (402.33) 641.25 (397.04) 467.34 (233.95)
*Data are presented as mean (SD). †p compared with controls <0.001. ‡p compared with patients in remission <0.01.
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A significant correlation was found between
the number of inflammatory parameters, as
defined in the methods section, and sICAM-1
concentrations (p < 0.05). No relation was
observed between circulating concentrations of
any other adhesion molecule studied and the
clinical features recorded.
Figure 1 shows the results from the longitu-
dinal substudy. In keeping with the data
obtained from the cross sectional study,
sICAM-1 values decreased when clinical re-
mission was achieved (from 369.63 (139.17) to
225.87 (64.25 ng/ml), p < 0.01), and remained
at low concentrations when treatment was
stopped (256.29 (75.15) ng/ml). A correlation
was found between sICAM-1 concentrations
and ESR values (Pearson’s correlation coeY-
cient, p = 0.034). No significant variation of
any of the other adhesion molecules studied
was observed in the longitudinal study.
Discussion
Our results indicate that sICAM-1 values were
increased in patients with active GCA com-
pared with values found in healthy matched
controls. Subsequently, sICAM-1 returned to
normal when clinical remission was achieved.
In contrast, circulating sICAM-3, sVCAM-1,
sE-selectin, and sL-selectin concentrations
remained unmodified throughout the course of
the disease.
Circulating adhesion molecules have been
studied in a variety of vasculitis syndromes.
Most of these studies include small series of
miscellaneous patients with diVerent vascu-
litides and, therefore, conclusions are diYcult
to draw. Studies performed in homogeneous
groups of patients have shown increased
concentrations of sICAM-1 and sVCAM-1,
but not sE-selectin, in patients with active
Wegener’s granulomatosis.6 Increased sE-
selectin and sICAM-1 concentrations have also
been demonstrated in patients with Kawasaki
disease.7 We have previously demonstrated an
increase in circulating sICAM-1, sVCAM-1,
sE-selectin, and a decrease in sL-selectin
concentrations in patients with classic polyar-
teritis nodosa.8 Variations in the circulating
pattern of soluble adhesion molecules in diVer-
ent vasculitides indicate a high complexity in
the regulatory pathways involved in adhesion
molecule expression and release and, probably,
a diversity in the source of circulating adhesion
molecules in each condition.
Immunopathological studies performed on
biopsy specimens obtained from homogeneous
series of patients with GCA and patients with
polyarteritis nodosa have demonstrated
E-selectin, ICAM-1, and VCAM-1 expression
in endothelia of inflammed vessels, particularly
in the adventitial microvasculature and neoves-
sels. Strong ICAM-1 and ICAM-3 expression as
well as occasional VCAM-1 expression have also
been observed in infiltrating leucocytes.9 10
However, and in contrast with our previous
findings in polyarteritis nodosa,8 only sICAM-1
was significantly increased in serum samples
from GCA patients. GCA involves large arteries
whereas polyarteritis nodosa involves medium
and small sized vessels. Consequently, the
endothelial surface contributing to the potential
release of adhesion molecules is much wider in
polyarteritis nodosa than in GCA. This fact
could account for the increased concentration of
sE-selectin, sICAM-1, and sVCAM-1 found in
polyarteritis nodosa and the lack of significantly
increased concentrations of adhesion molecules
of endothelial origin in GCA.
Interestingly, the pattern of circulating adhe-
sion molecules in our GCA patients is similar
to that found by Macchioni et al11 and Meliconi
et al12 in patients with polymyalgia rheumatica,
a condition closely related to GCA. Patients
with isolated polymyalgia rheumatica lack
significant inflammatory vascular lesions in
their arteries. Accordingly, it is not likely that
increased sICAM-1 found in both conditions is
generated in inflammed arteries. Circulating
activated monocytes are a characteristic feature
in both GCA and polymyalgia rheumatica13
and ICAM-1 is strongly expressed by activated
cells of the monocytic lineage.3 Activated
circulating monocytes could be a possible
source of increased circulating sICAM-1 found
in GCA and polymyalgia rheumatica, given the
absence of increase of circulating values of
other adhesion molecules of endothelial origin.
In vitro studies demonstrate that corticoster-
oid treatment down regulates adhesion mol-
ecule expression.14 According to this, we found
that raised concentrations of circulating
sICAM-1 returned to normal values upon cor-
ticosteroid treatment in our GCA patients. The
longitudinal study showed a good correlation
between sICAM-1 concentrations and clini-
cally apparent disease activity and acute phase
response as assessed by ESR measurement. A
decrease in sICAM-1 concentrations upon
corticosteroid treatment was also observed in
the cross sectional study although, because dif-
ferent patients were included in each group, it
was less apparent. In a previous study, we
showed that increased concentrations of circu-
lating soluble endothelial adhesion molecules
persist in patients with polyarteritis nodosa
despite corticosteroid treatment.8 We have also
shown persistence of abnormally high levels of
other products of endothelial origin such as
vWFAg in GCA patients.15 The clear decrease in
circulating sICAM-1 induced by corticosteroid
Figure 1 Soluble ICAM-1 concentrations and ESR values in the longitudinal study.
Error bars show standard error of the mean.
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treatment further supports a role for activated
circulating monocytes as a source of sICAM-1
in GCA patients as this cell subset is very sensi-
tive to the down regulatory eVects of
corticosteroids.13
Changes in circulating adhesion molecules
follow distinct patterns in diVerent inflamma-
tory diseases and show a certain level of
specificity even in related syndromes such as
the diVerent vasculitides. Studying fluctuations
of adhesion molecules along disease outcome
may improve our understanding about the par-
ticipation of diVerent cell types in the patho-
genesis of the inflammatory reaction in diVer-
ent disorders, the assessment of subclinical
disease activity and the eVects of treatment on
specific pathophysiological mechanisms.
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